Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.
Kiiskinen Tuomo et al. Nature medicine 2023 1
Little is known about the genetic determinants of medication use in preventing cardiometabolic diseases. Using the Finnish nationwide drug purchase registry with follow-up since 1995, we performed genome-wide association analyses of longitudinal patterns of medication use in hyperlipidemia, hypertension and type 2 diabetes in up to 193,933 individuals (55% women) in the FinnGen study. In meta-analyses of up to 567,671 individuals combining FinnGen with the Estonian Biobank and the UK Biobank, we discovered 333 independent loci (P?<?5?×?10–9) associated with medication use.
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium
B Moal et al, PLOS ONE, Jan 4, 2023
Among the 75,377 hospitalized patients with positive SARS-CoV-2 PCR, 1001 young adults presented with ARDS (7.8% of young hospitalized adults). Their mortality rate at 90 days was 16.2% and they presented with a similar complication rate for infection than older adults with ARDS. Peptic ulcer disease, paralysis, obesity, congestive heart failure, valvular disease, diabetes, chronic pulmonary disease and liver disease were associated with a higher risk of ARDS. We described a high prevalence of obesity (53%), hypertension (38%- although not significantly associated with ARDS), and diabetes (32%).
Feasibility of Precision Medicine in Hypertension Management—Scope and Technological Aspects
P Nitzan et al, J Per Med, November 7, 2022
While the use of genomic and proteomic personal features for widespread precision hypertension management is not practical, other features, such as age, ethnicity, and cardiovascular diseases, have been utilized in guidelines for hypertension management. In precision medicine, more blood-pressure-related clinical and physiological characteristics can be utilized for the determination of the threshold of hypertension and optimal treatment. Several non-invasive and simple-to-use techniques for the measurement of hypertension-related physiological features are suggested for use in precision management of hypertension
Preeclampsia, Genomics and Public Health
E Dawson et al, CDC Blog Post, October 25, 2022
Preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies and is one of the leading causes of maternal morbidity. Risk factors for preeclampsia include first pregnancy; history of preeclampsia; history of hypertension, chronic kidney disease, or both; history of thrombophilia (a condition that increases risk of blood clots); pregnancy from in vitro fertilization; family history of preeclampsia. A recent study identified a cell free RNA (cfRNA) signature that was promising in predicting pre-eclampsia several weeks before the onset of symptoms.